Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.

Katie Fitzgerald JonesMonica O'Reilly JacobJoanne SpetzLaurie HailerMatthew Tierney

Published in: Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing (2023)

One of the most robust tools to combat opioid overdose deaths is buprenorphine, a partial opioid agonist, and gold standard medication treatment for OUD, but only 5% of the prescribing workforce possess the required Drug Enforcement Agency (DEA) X waiver. A growing body of evidence demonstrates that Advanced Practice Registered Nurses are accelerating the growth in waiver update and buprenorphine use, despite the considerable barriers and limitations described in this policy analysis.

Keyphrases

healthcare
public health
primary care
mental health
chronic pain
adverse drug
emergency department
quality improvement